Product Name
Molecular Formula
C17H18N6
Molecular Weight
306.371
Storage
Store at -20°CÂ
Targets
JAK1Â
JAK2
IC50
3.3 nM
2.8 nM
Dosage
Stability
Solubility
Soluble in DMSO >Â 10 mM
General tips
For obtaining a higher solubility , please warm the tube at 37 ºC and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20ºC for several months.
Shipping Condition
Details:
Â
AZD9291
1421373-65-0
E7080
417716-92-8
Afatinib diMaleate
439081-18-2
XL184 S-MALATE
1140909-48-3
Crizotinib
877399-52-5
Axitinib
319460-85-0
WZ4002
1213269-23-8
Vandetanib
443913-73-3
Sunitinib
557795-19-4
Regorafenib
755037-03-7
Imatinib
152459-95-5
Foretinib
849217-64-7
trametinib
871700-17-3
Tivozanib
475108-18-0
PelitinibÂ
257933-82-7
Cediranib
288383-20-0
Selumetinib
606143-52-6
Tozasertib
639089-54-6
CapMatinib
1029712-80-8
Amuvatinib
850879-09-3
Lestaurtinib
111358-88-4
Brivanib
649735-46-6
To your satisfiction, here are our advantages:
1) Products can be sent out within 24 hours after payment.Â
====================================================
Â
Â
Â
Product Name
Molecular Formula
C17H18N6
Molecular Weight
306.371
Storage
Store at -20°CÂ
Targets
JAK1Â
JAK2
IC50
3.3 nM
2.8 nM
Dosage
Stability
Solubility
Soluble in DMSO >Â 10 mM
General tips
For obtaining a higher solubility , please warm the tube at 37 ºC and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20ºC for several months.
Shipping Condition
Details:
Â
AZD9291
1421373-65-0
E7080
417716-92-8
Afatinib diMaleate
439081-18-2
XL184 S-MALATE
1140909-48-3
Crizotinib
877399-52-5
Axitinib
319460-85-0
WZ4002
1213269-23-8
Vandetanib
443913-73-3
Sunitinib
557795-19-4
Regorafenib
755037-03-7
Imatinib
152459-95-5
Foretinib
849217-64-7
trametinib
871700-17-3
Tivozanib
475108-18-0
PelitinibÂ
257933-82-7
Cediranib
288383-20-0
Selumetinib
606143-52-6
Tozasertib
639089-54-6
CapMatinib
1029712-80-8
Amuvatinib
850879-09-3
Lestaurtinib
111358-88-4
Brivanib
649735-46-6
To your satisfiction, here are our advantages:
1) Products can be sent out within 24 hours after payment.Â
====================================================
Â
Â
Â
Myelofibrosis Treatment Raw Apis Ruxolitinib (CAS 941678-49-5)
Model NO.: 941678-49-5
Product Name: Ruxolitinib
CAS No.: 941678-49-5
Mf: C17h18n6
MW: 306.371
Delivery by: DHL, TNT, FedEx, Hkems, UPS, etc
Export Markets: Global
Trademark: NEWBIO
Transport Package: Aluminum Foil Bags
Specification: SGS
Origin: China
HS Code: 0000000000
Model NO.: 941678-49-5
Product Name: Ruxolitinib
CAS No.: 941678-49-5
Mf: C17h18n6
MW: 306.371
Delivery by: DHL, TNT, FedEx, Hkems, UPS, etc
Export Markets: Global
Trademark: NEWBIO
Transport Package: Aluminum Foil Bags
Specification: SGS
Origin: China
HS Code: 0000000000
Chemical Information:Ruxolitinib
75 mg/kg
3 years   - 20 ºC powder
6 months  -80 ºC dissolved in a solvent
Evaluation sample solution :Â ship with blue ice
All other available size: ship with RT , or blue ice upon request
Synonyms:Ruxolitinib;(R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;(betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile;1H-Pyrazole-1-propanenitrile,.beta.-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-,(.beta.R)-;(3R)-3-(4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;(3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyriMidin-4-yl}-1H-pyrazol-1-yl)propanenitrile;INCB018424 (Ruxolitinib);Jakafi
  Â
Description:INCB018424 is the first potent, selective inhibitor of JAK1/2 to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
Â
Â
Application:Mice receiving 75 mg/kg ruxolitinib or vehicle 6Â hours prior to and 6Â hours after injection of OVA/CpG were analyzed for expression of activation markers on CD11c 1CD81 splenic DCs. Lower expression levels of CD40, CD80, CD86 as well as MHC IÂ and II molecules were detected in ruxolitinib-challenged animals. Next, ruxolitinib or vehicle was fed to mice 6Â hours prior to as well as 6Â hours and 18 hours after priming with OVA/CpG and adoptive transfer of CFSE-labeled OT-I cells. Analysis of transferred CFSE-labeled OT-I TÂ cells revealed reduced proliferation, CD25 expression, and IFN-production in mice pretreated with ruxolitinib.
Â
1.The parcels will be sent within 24 hours once the order is verified.
2.Packaging is fully in accordance with customer demand.
3.There will be discounts whether you are an old customer or not.
Chemical Information:2) Secure and discreet shipment.Â
3) Various methods for your choice, like DHL/TNT/FedEx/SF-express.
Contact:
Telephone: +86-027-87002705
Mobile:Â +86-13638641831 +86-13277093700
FaceBook:Â https://www.facebook.com/newbiopharma/
Website:Â Â http://www.newbiopharm.com/
Online Store:Â http://biocar.en.made-in-china.com/
©Wuhan Newbio Pharm-Tech Co., Ltd.
Ruxolitinib
75 mg/kg
3 years   - 20 ºC powder
6 months  -80 ºC dissolved in a solvent
Evaluation sample solution :Â ship with blue ice
All other available size: ship with RT , or blue ice upon request
Synonyms:Ruxolitinib;(R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;(betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile;1H-Pyrazole-1-propanenitrile,.beta.-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-,(.beta.R)-;(3R)-3-(4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;(3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyriMidin-4-yl}-1H-pyrazol-1-yl)propanenitrile;INCB018424 (Ruxolitinib);Jakafi
  Â
Description:INCB018424 is the first potent, selective inhibitor of JAK1/2 to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3.
Â
Â
Application:Mice receiving 75 mg/kg ruxolitinib or vehicle 6Â hours prior to and 6Â hours after injection of OVA/CpG were analyzed for expression of activation markers on CD11c 1CD81 splenic DCs. Lower expression levels of CD40, CD80, CD86 as well as MHC IÂ and II molecules were detected in ruxolitinib-challenged animals. Next, ruxolitinib or vehicle was fed to mice 6Â hours prior to as well as 6Â hours and 18 hours after priming with OVA/CpG and adoptive transfer of CFSE-labeled OT-I cells. Analysis of transferred CFSE-labeled OT-I TÂ cells revealed reduced proliferation, CD25 expression, and IFN-production in mice pretreated with ruxolitinib.
Â
1.The parcels will be sent within 24 hours once the order is verified.
2.Packaging is fully in accordance with customer demand.
3.There will be discounts whether you are an old customer or not.
2) Secure and discreet shipment.Â
3) Various methods for your choice, like DHL/TNT/FedEx/SF-express.
Contact:
Telephone: +86-027-87002705
Mobile:Â +86-13638641831 +86-13277093700
FaceBook:Â https://www.facebook.com/newbiopharma/
Website:Â Â http://www.newbiopharm.com/
Online Store:Â http://biocar.en.made-in-china.com/
©Wuhan Newbio Pharm-Tech Co., Ltd.